JP2020506205A5 - - Google Patents

Download PDF

Info

Publication number
JP2020506205A5
JP2020506205A5 JP2019542722A JP2019542722A JP2020506205A5 JP 2020506205 A5 JP2020506205 A5 JP 2020506205A5 JP 2019542722 A JP2019542722 A JP 2019542722A JP 2019542722 A JP2019542722 A JP 2019542722A JP 2020506205 A5 JP2020506205 A5 JP 2020506205A5
Authority
JP
Japan
Prior art keywords
group
alkyl
heterocyclyl
cycloalkyl
optionally
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Granted
Application number
JP2019542722A
Other languages
English (en)
Japanese (ja)
Other versions
JP7049353B2 (ja
JP2020506205A (ja
Filing date
Publication date
Application filed filed Critical
Priority claimed from PCT/EP2018/052620 external-priority patent/WO2018146008A1/en
Publication of JP2020506205A publication Critical patent/JP2020506205A/ja
Publication of JP2020506205A5 publication Critical patent/JP2020506205A5/ja
Application granted granted Critical
Publication of JP7049353B2 publication Critical patent/JP7049353B2/ja
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

JP2019542722A 2017-02-08 2018-02-02 糖尿病の治療のためのインダニルアミノアザジヒドロベンゾフラニル酢酸、医薬組成物 Active JP7049353B2 (ja)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
EP17155191 2017-02-08
EP17155191.4 2017-02-08
PCT/EP2018/052620 WO2018146008A1 (en) 2017-02-08 2018-02-02 Indanylaminoazadihydrobenzofuranylacetic acids, pharmaceutical compositions for the treatment of diabetes

Publications (3)

Publication Number Publication Date
JP2020506205A JP2020506205A (ja) 2020-02-27
JP2020506205A5 true JP2020506205A5 (enExample) 2021-01-14
JP7049353B2 JP7049353B2 (ja) 2022-04-06

Family

ID=57995116

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2019542722A Active JP7049353B2 (ja) 2017-02-08 2018-02-02 糖尿病の治療のためのインダニルアミノアザジヒドロベンゾフラニル酢酸、医薬組成物

Country Status (5)

Country Link
US (1) US10550127B1 (enExample)
EP (1) EP3580222B1 (enExample)
JP (1) JP7049353B2 (enExample)
CN (1) CN110300755B (enExample)
WO (1) WO2018146008A1 (enExample)

Families Citing this family (15)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US10793530B2 (en) 2017-01-26 2020-10-06 Boehringer Ingelheim International Gmbh Benzylaminopyrazinylcyclopropanecarboxylic acids, pharmaceutical compositions and uses thereof
WO2018138030A1 (en) 2017-01-26 2018-08-02 Boehringer Ingelheim International Gmbh Benzyloxypyrazinylcyclopropanecarboxylic acids, pharmaceutical compositions and uses thereof
US10919859B2 (en) 2017-01-26 2021-02-16 Boehringer Ingelheim International Gmbh Benzylaminopyridylcyclopropanecarboxylic acids, pharmaceutical compositions and uses thereof
CN110198928B (zh) 2017-01-26 2023-08-29 勃林格殷格翰国际有限公司 苄氧基吡啶基环丙烷甲酸、其药物组合物和用途
JP7049353B2 (ja) 2017-02-08 2022-04-06 ベーリンガー インゲルハイム インターナショナル ゲゼルシャフト ミット ベシュレンクテル ハフツング 糖尿病の治療のためのインダニルアミノアザジヒドロベンゾフラニル酢酸、医薬組成物
BR102018007822A2 (pt) 2017-04-20 2018-11-06 Gilead Sciences, Inc. composto, métodos para inibir pd-1, pd-l1 e/ou interação de pd-1/pd-l1 e para tratamento de câncer, composição farmacêutica, e, kit para tratamento de ou prevenção de câncer ou uma doença ou condição
CR20200347A (es) 2018-02-13 2020-09-23 Gilead Sciences Inc Inhibidores pd-1/pd-l1
US12083118B2 (en) 2018-03-29 2024-09-10 Arbutus Biopharma Corporation Substituted 1,1′-biphenyl compounds, analogues thereof, and methods using same
TWI712412B (zh) 2018-04-19 2020-12-11 美商基利科學股份有限公司 Pd‐1/pd‐l1抑制劑
SG11202012425QA (en) 2018-07-13 2021-01-28 Gilead Sciences Inc Pd-1/pd-l1 inhibitors
WO2020086556A1 (en) 2018-10-24 2020-04-30 Gilead Sciences, Inc. Pd-1/pd-l1 inhibitors
KR20220150270A (ko) 2019-10-07 2022-11-10 칼리오페, 인크. Gpr119 효능제
TW202140440A (zh) 2020-02-28 2021-11-01 美商克力歐普股份有限公司 Gpr40激動劑
WO2021236617A1 (en) 2020-05-19 2021-11-25 Kallyope, Inc. Ampk activators
CN116390925A (zh) 2020-06-26 2023-07-04 卡尔优普公司 Ampk活化剂

Family Cites Families (35)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US2505322A (en) 1945-09-14 1950-04-25 Gibson Refrigerator Co Refrigerator cabinet
US2560111A (en) 1946-11-07 1951-07-10 Raymond T Levine Buffing chuck
US2656003A (en) 1948-02-27 1953-10-20 Inst Of Inventive Res High explosive disk-shaped charge for seismic exploration
US2727340A (en) 1953-08-31 1955-12-20 Alfred S Zanotta Portable tool for reconditioning crane rails
US5356287A (en) 1987-03-16 1994-10-18 Mcintyre Kevin M Simulating presence
CA2505322A1 (en) 2002-11-08 2004-05-21 Takeda Pharmaceutical Company Limited Receptor function regulator
US7135575B2 (en) 2003-03-03 2006-11-14 Array Biopharma, Inc. P38 inhibitors and methods of use thereof
EP1630152A4 (en) 2003-05-30 2009-09-23 Takeda Pharmaceutical CONDENSED CYCLIC COMPOUND
US7834013B2 (en) 2003-11-19 2010-11-16 Glaxosmithkline Llc Aminophenylcyclopropyl carboxylic acids and derivatives as agonists to GPR40
JP4875978B2 (ja) 2004-03-15 2012-02-15 武田薬品工業株式会社 アミノフェニルプロパン酸誘導体
US7664629B2 (en) 2005-07-19 2010-02-16 Xerox Corporation Second language writing advisor
EP1916234B1 (en) 2005-07-29 2014-11-12 Takeda Pharmaceutical Company Limited Cyclopropanecarboxylic acid compound
EP1924546A1 (en) 2005-09-14 2008-05-28 Amgen, Inc Conformationally constrained 3- (4-hydroxy-phenyl) - substituted-propanoic acids useful for treating metabolic disorders
KR20080103584A (ko) 2006-03-30 2008-11-27 아사히 가세이 파마 가부시키가이샤 치환 이환식 환상 유도체 및 그 용도
RS53230B (sr) 2006-06-27 2014-08-29 Takeda Pharmaceutical Company Limited Kondenzovana ciklična jedinjenja kao modulatori gpr40 receptora
TW200838526A (en) 2006-12-01 2008-10-01 Astellas Pharma Inc Carboxylic acid derivatives
KR20110027657A (ko) 2008-06-25 2011-03-16 다이이찌 산쿄 가부시키가이샤 카르복실산 화합물
ES2345916B1 (es) 2008-10-14 2011-09-14 Clipdorfix, S.L. Dispositivo de fijacion liberable de elementos adosados.
AU2009303475B2 (en) 2008-10-15 2012-09-13 Amgen Inc. Spirocyclic GPR40 modulators
WO2010143733A1 (en) * 2009-06-09 2010-12-16 Takeda Pharmaceutical Company Limited Novel fused cyclic compound and use thereof
TW201643169A (zh) 2010-07-09 2016-12-16 艾伯維股份有限公司 作為s1p調節劑的螺-哌啶衍生物
DK2646425T3 (en) 2010-12-01 2015-08-24 Boehringer Ingelheim Int Indanyloxydihydrobenzofuranylacetic acids useful for the treatment of metabolic syndrome.
US8642585B2 (en) 2012-03-26 2014-02-04 Boehringer Ingelheim International Gmbh Indanyloxydihydrobenzofuranylacetic acids
US8633182B2 (en) 2012-05-30 2014-01-21 Boehringer Ingelheim International Gmbh Indanyloxyphenylcyclopropanecarboxylic acids
WO2014019186A1 (en) 2012-08-02 2014-02-06 Merck Sharp & Dohme Corp. Antidiabetic tricyclic compounds
EP2925748B1 (en) * 2012-11-28 2017-01-11 Boehringer Ingelheim International GmbH Indanyloxydihydrobenzofuranylacetic acids as modulators of the g-protein coupled receptor 40 (gpr40) and of the free fatty acid receptor 1 (ffar1) for the treatment of metabolic diseases
US20140163025A1 (en) 2012-12-07 2014-06-12 Boehringer Ingelheim International Gmbh Indanyloxydihydrobenzofuranylacetic acids
EP2963027B1 (en) 2013-02-28 2018-12-26 TiumBio Co., Ltd. Tricyclic compound and use thereof
CN105473595A (zh) 2013-08-23 2016-04-06 福建海西新药创制有限公司 治疗糖尿病的羧酸化合物
EP3074375B1 (en) * 2013-11-28 2018-04-04 Boehringer Ingelheim International GmbH New indanyloxyphenylcyclopropanecarboxylic acids
CN105001212B (zh) * 2014-04-16 2018-01-16 江苏柯菲平医药股份有限公司 稠环化合物及其制备方法和应用
EP3347358B1 (en) * 2015-09-09 2019-11-27 Boehringer Ingelheim International GmbH [{[2,3-dihydro-1h-inden-1-yl]amino}-2h,3h-furo[3,2-b]pyridin-3-yl]acetic acids, pharmaceutical compositions and uses thereof
CN105820396A (zh) 2016-04-22 2016-08-03 宁波硫华聚合物有限公司 橡胶促进剂四硫化双五亚甲基秋兰姆预分散母胶粒及其制备方法
CN110198928B (zh) 2017-01-26 2023-08-29 勃林格殷格翰国际有限公司 苄氧基吡啶基环丙烷甲酸、其药物组合物和用途
JP7049353B2 (ja) 2017-02-08 2022-04-06 ベーリンガー インゲルハイム インターナショナル ゲゼルシャフト ミット ベシュレンクテル ハフツング 糖尿病の治療のためのインダニルアミノアザジヒドロベンゾフラニル酢酸、医薬組成物

Similar Documents

Publication Publication Date Title
JP2020506205A5 (enExample)
JP2020505402A5 (enExample)
JP2020514315A5 (enExample)
JP2020505400A5 (enExample)
JP2020505393A5 (enExample)
JP2020505394A5 (enExample)
JP2019535792A5 (enExample)
RU2403258C2 (ru) Тиазолилдигидроиндазолы
RU2495044C2 (ru) Ингибиторы активности протеинтирозинкиназы
JP2018526405A5 (enExample)
RU2309951C2 (ru) Производные никотинамида, способы их получения, фармацевтическая композиция на их основе и применение
JP2018526352A5 (enExample)
RU2021139070A (ru) Ингибиторы ERBB/BTK
JP2016534084A5 (enExample)
RU2019133646A (ru) Изохинолины в качестве ингибиторов hpk1
JP2018522879A5 (enExample)
RU2005116254A (ru) Производные пиридопирролизина и пиридоиндолизина
JP2019513778A5 (enExample)
JP2012513416A5 (enExample)
RU2005105683A (ru) Обладающие ингибирующим действием на vegfr-2 и vegfr-3 антраниламидопиридины
RU2019130519A (ru) 4-пиридоновое соединение или его соль, фармацевтическая композиция и содержащий их состав
RU2020102453A (ru) Фармацевтические композиции
JP2017503760A5 (enExample)
JP2019504050A5 (enExample)
JP2014509600A5 (enExample)